Abstract: The incidence of breast cancer (BC) is on the rise. The effective and precise management of BC continues to be topical. Tumor infiltrating lymphocytes (TILs), significant biomarkers indicative of the biological behavior of BC, have not been well recognized in clinical practice. There are some impediments, including the lack of a standard protocol for the quantification of TILs, an optimized threshold for TILs, and a repeatable noninvasive method for the assessment of TILs. These issues are the major controversies preventing the use of TILs as biomarkers in the clinical management of BC. Nevertheless, the value of TILs as biomarkers in the assessment of the prognosis and prediction of the response to treatment cannot be neglected, as they show promise in promoting precise and individualized management of BC. We aimed to offer a comprehensive outline of the current controversies and consensus regarding TILs as biomarkers in the management of BC, with the aim of providing a basis for the rational application of TILs as biomarkers.